home All News open_in_new Full Article

China’s biotech industry is gaining on the US. Can tariffs hold them back?

In the summer of 2015, a time when China’s pharmaceutical market was in a phase of rapid expansion, a sudden regulatory change sent tremors through the industry: drug companies would need to audit the clinical trial data for all pending applications. If withdrawn within a month of the announcement, firms could avoid penalties for submitting flawed applications, but hiding or falsifying data would court severe punishments, including multi-year filing bans. The response from the industry indicated...


today 2 h. ago attach_file Economics

attach_file Economics
attach_file Events
attach_file Economics
attach_file Politics
attach_file Events
attach_file Economics
attach_file Events
attach_file Economics
attach_file Events
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Economics


ID: 1780772374
Add Watch Country

arrow_drop_down